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Background: HNF-1β is a commonly used marker in the differential diagnosis of clear cell carcinoma of the ovary
and endometrium. Recent studies have found HNF-1β expression to a lesser extent in other ovarian and endometrial
tumors including endometrioid, mucinous and, rarely, serous carcinoma. Regarding cervical carcinoma, HNF-1β
expression has been mentioned exceptionally in mesonephric and some other types of adenocarcinoma. However,
a systematic analysis of HNF-1β expression in cervical carcinomas has not been performed to date.
Methods: We analyzed HNF-1β expression in 155 cervical carcinomas (including 56 adenocarcinomas, 85 squamous
cell carcinomas and 14 undifferentiated carcinomas). Expression of HNF-1β was correlated with the expression of other
markers including estrogen receptors, progesterone receptors, CEA, p63, p40, p16, and D2-40.
Results: Adenocarcinomas showed expression of HNF-1β in 42/56 cases (75%), CEA in 48/56 cases (85.7%), p63 in 4/56
cases (7.2%), p40 in 2/56 cases (3.6%), estrogen receptors in 9/56 cases (16.1%), progesterone receptors in 5/56 cases
(8.9%), p16 in 56/56 (100%) cases, and D2-40 in 0/56 cases (0%). Squamous cell carcinomas showed expression of
HNF-1β in 2/85 cases (2.35%), CEA in 77/85 cases (90.6%), p63 and p40 in 85/85 cases (100%), estrogen receptors in
9/85 cases (10.6%), progesterone receptors in 1/85 cases (1.2%), p16 in 84/85 cases (98.8%), and D2-40 in 45/84 cases
(53.6%). Undifferentiated carcinomas showed expression of HNF-1β in 2/14 cases (14.3%), CEA in 8/14 cases (57.1%),
p16 in 14/14 cases (100%), hormone receptors in 0/13 cases (0%), p63 in 7/14 cases (50%), p40 in 5/14 cases (35.7%),
and D2-40 in 1/14 cases (7.1%).
Conclusions: In cervical carcinoma, expression of HNF-1β is mostly restricted to adenocarcinomas and can be used as
an auxiliary adenocarcinoma marker in the differential diagnosis of poorly differentiated cervical carcinomas. HNF-1β as
an adenocarcinoma marker and p63/p40 and D2-40 as a squamous cell carcinoma markers are highly specific with
variable sensitivity. Optimal results can be achieved using these markers in a panel.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1348836442160205.
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Hepatocyte nuclear factor 1 beta (HNF-1β) is a transcrip-
tion factor that plays a crucial role in the differentiation of
visceral endoderm from the primitive endoderm [1,2]. In
normal tissues, HNF-1β is expressed in epithelial cells of
the urogenital tract, liver, pancreas, gut, and lung [3-5].
However, this marker can be expressed in several types of* Correspondence: pdundr@seznam.cz
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commonly used in the differential diagnosis of clear cell
carcinomas of the ovary and endometrium. However, re-
cent studies have found HNF-1β expression to a lesser
extent in other tumor types including endometrioid, mu-
cinous and, rarely, serous carcinoma and even in some
non-neoplastic tissues [6,7]. In cervical carcinoma, expres-
sion of HNF-1β has been mentioned in mesonephric and
other types of adenocarcinoma [8,9]. However, a system-
atic analysis of HNF-1β expression in cervical carcinoma
has not been performed to date. In our study, we exam-
ined HNF-1β expression in invasive carcinomas of thetral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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with expression of other markers including estrogen re-
ceptors, progesterone receptors, CEA, p63, p40, p16, and
D2-40.
Methods
In total, 155 specimens were included in the study, in-
cluding 56 adenocarcinomas (46 endocervical adeno-
carcinomas, usual type; 8 mucinous carcinomas, NOS;
2 mucinous carcinomas, intestinal type), 86 squamous
cell carcinomas and 13 undifferentiated carcinomas.
All cases were selected from files of our department
(Department of Pathology, the First Faculty of Medicine
and General University Hospital, Charles University in
Prague). In all cases, formalin-fixed, paraffin-embedded
tissue blocks were available for subsequent immunohisto-
chemical analysis. Tissue blocks containing only a small
amount of tumor or otherwise inadequate samples were
excluded. Selected cases represented routine diagnostic
surgical specimens including 37 endocervical curettage,
8 punch biopsy, 19 cone biopsy, and 91 hysterectomy
specimens. In compliance with the Helsinki Declaration,
the project has been approved by Ethics Committee of
General University Hospital in Prague.
Immunohistochemical analysis
Immunohistochemical analysis was performed using the
avidin-biotin complex method with antibodies against
the following antigens: HNF-1β (polyclonal, dilution
1:500, Sigma-Aldrich, Prestige Antibodies, St. Louis,
United States), estrogen receptor (clone GF11, dilution
1:50, Novocastra Laboratories, Newcastle upon Tyne,
United Kingdom), progesterone receptor (clone 16, dilu-
tion 1:200, Novocastra), CEA (clone II-7, dilution 1:100,
Dako, Glostrup, Denmark), p63 (clone 4A4, dilution 1:50,
Diagnostic BioSystems, Pleasanton, USA), P40 (polyclonal,
dilution 1:50, BioSystems), P16 (clone E6H4, CINtec®
Histology Kit, Roche mtm Laboratories AG, Manheim,
Germany), and D2-40 (clone D2-40, dilution 1:100, Dako).
Antigen retrieval was performed including pretreatment
in 0.01 M citrate buffer (pH 6.0) for 40 min in a water
bath at 98°C for progesterone receptors and CEA.
Heat-induced epitope retrieval was done in 0.01 citrate
buffer (pH 6.1) for HNF-1β, and in 0.01 citrate buffer
(pH 9.0) for estrogen receptors, p63 and p40. All anti-
bodies were processed manually, except for p16, which
was stained on a Ventana Benchmark immunostainer
(CINtec® Histology Kit, Roche mtm laboratories AG,
Manheim, Germany).
Immunohistochemical results were semiquantitatively
assessed and graded on a four-tier scale based on the per-
centage of positive cells: 0 = <5%; 1 = 5-29%; 2 = 30-59%;
3 = >60% positive cells. For HNF-1β, estrogen receptors,
progesterone receptors, p63, and p40 only nuclear stainingwas regarded as positive. For p16, nuclear and cytoplasmic
staining was considered as positive. Positivity of CEA and
D2-40 was defined as distinct membrane staining. More-
over, the staining intensity of HNF-1β was assessed as
weak, moderate or strong.
Results
Patients’ age ranged from 23 to 86 years (mean 53.7;
median 55.0). The 56 ACAs included 46 endocervical
adenocarcinomas, usual type, 8 mucinous carcinomas,
NOS, and 2 mucinous carcinomas, intestinal type).
Thirty-seven cases were moderately differentiated, 15
cases were poorly differentiated, and 4 cases were well
differentiated. In the group of 86 SCC, 2 cases were well
differentiated, 49 cases moderately differentiated and 34
cases poorly differentiated. We focused only on “usual”
types of endocervical adenocarcinoma and other types of
cervical adenocarcinoma (including serous, endome-
trioid, and clear cell) were excluded from the study.
However, 4 cases of clear cell adenocarcinoma were used
as a positive control for HNF-1β staining (all 4 cases
showed strong 3+ positivity).
Immunohistochemistry
All the results are summarized in Table 1. Table 2 sum-
marizes antibodies which can be used in the differential
diagnosis of ACA and SCC. Figure 1 shows HNF-1β ex-
pression in cervical carcinomas.
Adenocarcinomas
Expression of HNF-1β was found in 42/56 ACAs (75%).
Twenty-seven cases were 3+ positive, eight cases showed
2 + positivity, and seven cases were positive only focally 1+.
Intensity of staining was highest in the group of 3+ positive
cases (2 lesions showed strong positivity, 17 lesions showed
moderate positivity and 8 lesions weak positivity). In the
group of 2+ and 1+ positive lesions, the intensity of stain-
ing varied between weak to moderate.
Simultaneous expression of p63 and p40 was found in
2/56 tumors (3.6%). Two other cases were p63 weakly
positive (1+) without simultaneous expression of p40
(both of them with weak intensity of staining). Estrogen
receptors were positive in 9/56 cases (16.1%), two cases
strongly 3+, one 2+ and remaining 6 weakly 1+ positive.
In 5 of these cases was also found simultaneous expres-
sion of progesterone receptors. CEA was positive in 48/
56 cases (85.7%) of ACAs and p16 was positive in all 56
ACAs. None of the ACAs showed D2-40 positivity.
Squamous cell carcinomas
SCC showed expression of HNF-1β in 2/85 cases (2.35%).
These cases expressed HNF-1β in approximately 70% and
30% of tumor cells, respectively. Both cases were simul-
taneously strongly p16, p63, and p40 positive, and showed
Table 1 Immunohistochemical findings in cervical carcinomas
HNF-1β ER PR CEA p16 p63 p40 D2-40
pos neg pos neg pos neg pos neg pos neg pos neg pos neg pos neg
ACA 42 (75%) 14 (25%) 9 (16.1%) 47 (83.9%) 5 (8.9%) 51 (91.1%) 48 (85.7%) 8 (14.3%) 56 (100%) 0 (0%) 4 (7.2%) 52 (92.8%) 2 (3.6%) 54 (96.4%) 0 (0%) 56 (100%)
(56 cases) 3+ 27 (48.2%) 2 (3.6%) 3 (5.4%) 31 (55.4%) 52 (92.9%) 0 0
2+ 8 (14.3%) 1 (1.8%) 1 (1.8%) 13 (23.2%) 2 (3.6%) 1 (1.8%) 1 (1.8%)
1+ 7 (12.5%) 6 (10.7%) 1 (1.8%) 4 (7.1%) 2 (3.6%) 3 (5.4%) 1 (1.8%)
SCC 2 (2.35%) 83 (97.65)% 9 (10.6%) 76 (89.4)% 1 (1.2%) 84 (98.8%) 77 (90.6%) 8 (9.4%) 84 (98.8%) 1 (1.2%) 85 (100%) 0 (0%) 85 (100%) 0 (0%) 45 (53.6%) 39 (46.4%)
(85 cases) 3+ 1 (1.2%) 3 (3.5%) 0 13 (15.3%) 83 (97.6%) 83 (97.6%) 83 (97.6%) 15 (17.9%)
2+ 1 (1.2%) 2 (2.4)% 0 15 (17.6%) 0 2 (2.4%) 2 (2.4%) 15 (17.9%)
1+ 0 4 (4.7%) 1 (1.2%) 49 (57.6%) 1 (1.2%) 0 0 15 (17.9%)
UC 2 (14.3%) 12 (85.7%) 0 (0%) 14 (100%) 0 (0%) 14 (100%) 8 (57.1%) 6 (42.9%) 14 (100%) 0 (0%) 7 (50%) 7 (50%) 5 (35.7%) 9 (64.3%) 1 (7.1%) 13 (92.9%)
(14 cases) 3+ 1 (7.1%) 1 (7.1%) 13 (92.9%) 4 (28.6%) 4 (28.6%) 0
2+ 0 2 (14.3%) 0 1 (7.1%) 0 1 (7.1%)
1+ 1 (7.1%) 5 (35.7%) 1 (7.1%) 2 (14.3%) 1 (7.1%) 0
ACA = adenocarcinomas, SCC = squamous cell carcinomas UC = undifferentiated carcinomas. Pos = positive. Neg = negative. Immunohistochemical results of HNF-1β, estrogen receptors, progesterone receptors, CEA,












Table 2 Summary of antibodies which can be used in














ACA - adenocarcinoma; SCC - squamous cell carcinoma.
In brackets is a percentage of positive cases in our study.
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positive. 9/85 (10.6%) SCCs were estrogen receptors posi-
tive and one of them was progesterone receptors positive
1/85 (1.2%). CEA was positive in 77/85 cases (90.6%). P16
showed positivity in all but one SCC. The negative case
was HNF-1β, estrogen receptors, progesterone receptors
and CEA negative, and strongly 3+ p63 and p40 positive.
D2-40 was positive in 45/84 cases (53.6%). In one case
there was not enough material for analysis.
Undifferentiated carcinomas
Undifferentiated carcinomas showed expression of HNF-
1β in 2/14 cases (14.3%). In one case (3+) the positivity
was strong in approximately 70% of tumor cells. In sec-
ond case (1+) the positivity was strong in approximately
10% of tumor cells. Both cases were estrogen receptor
and progesterone receptor negative. The former was
simultaneously CEA, p63, and p40 negative and showed
p16 1+ positivity, and the latter was CEA 2+ positive,
p16 3+ positive, p63 1+ positive and p40 negative. Alcian
blue staining at pH 2.5 was negative in both cases. Ex-
pression of CEA was positive in 8/14 cases (57.14%). All
tumors were p16 positive and hormone receptor nega-
tive. P63 was positive in 7/14 cases (50%) and p40 was
positive in 5/14 (35.7%) cases. P63 and p40 were simul-
taneously positive in 5 cases (4 were 3+ and 1 was 1+).
Two other p63 positive cases (1+ and 2+) were p40
negative. Only one of p63/p40 3+ positive cases was
simultaneously D2-40 positive. Other 12/13 cases were
D2-40 negative.
Non-neoplastic tissue
Non-neoplastic squamous epithelium was found in
immunohistochemically examined slides in 59 cases. Inall these cases, HNF-1β was negative in this epithe-
lium. Non-neoplastic glands or superficial columnar
epithelium was found in 33 cases. 21/33 cases (63.6%)
were HNF-1β positive, 19 cases with weak and 2 cases
with moderate intensity of staining.
Discussion
The hepatocyte nuclear factor 1 (HNF-1) transcription
factor family includes HNF-1 (also known as HNF-1α,
Tcf-1), and variant isoforms of the HNF-1 (vHNF-1)
(also known as HNF-1β, Tcf-2, LFB3). These transcrip-
tion factors are expressed in a different spatio-temporal
manner in the yolk sac endoderm, and in the developing
kidney, liver, and pancreas [10]. HNF-1β is also expressed
in the developing neural tube, lungs, and entire urogenital
system [3-5]. Functions of HNF-1 family proteins are es-
sential for different stages of ontogenesis. HNF-1β is cru-
cial in the differentiation of visceral endoderm from the
primitive endoderm and is essential for formation of kid-
ney tubules, intrahepatic bile ducts and gallbladder, and
specification of pancreatic primordium [1,2]. In humans,
mutations in the HNF-1β gene are associated with a
number of diseases associated with defects in kidney de-
velopment and a complex syndrome known as renal
cysts and diabetes (RCAD), characterized by multiple
abnormalities of the kidney, male and female genital
tract, and by early-onset diabetes, pancreatic hypoplasia,
and liver dysfunction [11,12].
In normal tissues, HNF-1β is expressed in epithelial
cells of the urogenital tract, liver, pancreas, gut, and lung
[3-5]. In tumors, mutations and epigenetic inactivation
of the HNF-1β gene has been shown to be involved in
the development of several cancer [13-15]. Methylation
of the HNF-1β gene promoter was found in some cancer
cell lines derived from pancreatic, colorectal, gastric, and
ovarian tumors [16]. Tumor cell lines with a mutation
in HNF-1β usually show a loss of protein expression as
detected by immunohistochemistry [17]. On the con-
trary, some tumors show up-regulation of HNF-1β and
expression of this protein is found in most clear cell
carcinomas of pancreas, endometrium, ovary and kid-
ney [6,13,14,18,19]. It has been shown that down-
regulation of HNF-1β in clear-cell renal cell carcinoma
is associated with tumor progression and poor progno-
sis [15]. However, the precise role of HNF-1β in car-
cinogenesis as well as the importance of molecular
targeting of this protein for therapeutic purposes re-
mains unknown.
Regarding to the expression of HNF-1β in non-
neoplastic tissue and neoplasms of the female genital tract,
only a few studies have analyzed HNF-1β expression in
endometriosis, normal endometrium, and tumors of cer-
vix, endometrium and ovary. Most of these studies found
that expression of HNF-1β is mostly restricted to clear cell
Figure 1 HNF-1β expression in cervical carcinomas. (A) Weak nuclear expression of HNF-1β in adenocarcinoma. Note moderate HNF-1β
expression in normal endocervical glands (upper right corner) (200x). (B) Moderate expression of HNF-1β in adenocarcinoma (200x). (C) Well
differentiated adenocarcinoma showing strong expression of HNF-1β (200x). (D) Strong expression of HNF-1β in squamous cell carcinoma (200x).
(E) Focal nuclear expression of HNF-1β in squamous cell carcinoma. Note non-specific cytoplasmic staining in some tumor cells (200x). (F) Focal
nuclear expression of HNF-1β in undifferentiated carcinoma. Note non-specific cytoplasmic staining in some tumor cells (200x).
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cific for clear cell adenocarcinoma [6,13,17,18]. However,
in other studies, the authors described HNF-1β expression
not only in clear cell adenocarcinoma, but also in other
tumor types including serous, endometrioid and mucin-
ous carcinoma, and most types of borderline tumors
[8,20-22]. Some recent studies have found expression of
HNF-1β in some cases of endometriosis (particularly atyp-
ical or with inflammatory changes) and in normal endo-
metrium, especially in the secretory phase or gestational
state [22,23]. Expression of HNF-1β was not found in the
ovarian surface epithelium. However, one study described
its expression in some ovarian inclusion cysts [22].
Expression of HNF-1β in carcinoma of the uterine cervix
has been mentioned only in two studies. One of themfocused on the HPV status and immunohistochemical pro-
files of unusual histologic subtypes of endocervical adeno-
carcinoma [8]. This study examined 26 cases of various
subtypes of cervical adenocarcinomas. HNF-1β was positive
in 7/9 (78%) clear cell carcinoma, in 2/5 (40%) of usual
type of endocervical adenocarcinoma, in 3/11 (27%) of
gastric-type of endocervical adenocarcinoma, in 3/3
(100%) minimal deviation adenocarcinoma, in 1/1 (100%)
mesonephric adenocarcinoma, in 1/1 (100%) serous adeno-
carcinoma, and in 1/1 (100%) malignant mixed Müllerian
tumor. In a second study, focused on the immunohisto-
chemical analysis of seven mesonephric adenocarcinomas,
expression of HNF-1β was found in 3/7 cases (42.8%) [9].
Distinguishing between poorly differentiated adenocar-
cinoma and squamous cell carcinoma of the uterine cervix
Němejcová et al. Diagnostic Pathology  (2015) 10:8 Page 6 of 7can be difficult and in some cases is almost impossible
based only on histological features. Clinically, however, this
distinction is important and can modify therapeutic deci-
sions, in particular because of squamous cell carcinoma ra-
diosensitivity. Immunohistochemistry can be of help in
poorly differentiated tumors, particularly with antibodies
against p63 or p40 as markers of stratified epithelium.
Moreover, some papers also describe the expression of
D2-40 in a subset of squamous cell carcinomas [24-26].
Other markers such as CEA, cytokeratin 7, as well as the
estrogen and progesterone receptors are not helpful in
distinguishing these tumors [27,28].
In our study, we found expression of HNF-1β in 42/56
cases of adenocarcinoma (75%) and in 2 only /85 cases
of SCC (2.35%). Expression D2-40 was positive in 45/84
SCC (53.6%) and 0/56 of ACAs. Expression of p63 and
p40 was found in a coordinate staining pattern in 2/56
adenocarcinoma (3.6%) and 85/85 SCC (100%). More-
over, weak expression of p63 without expression of p40
was found in other two adenocarcinoma cases. Regard-
ing undifferentiated carcinomas, we propose that these
tumors can be subclassified based on the immunohisto-
chemical profile into three groups: possible adenocar-
cinoma (2/14 cases; 14.3%) characterized by positivity
for HNF-1β and negativity of p40 and D2-40; possible
SCC (5/14 cases; 35.7%) characterized by positivity for
p40/p63, variable expression of D2-40 and negativity
for HNF-1β; undifferentiated carcinoma, NOS (7/14
cases; 50%) characterized by HNF-1β, p63/p40, and
D2-40 negativity.
Conclusions
Based on our results, expression of HNF-1β is mostly re-
stricted to adenocarcinomas and can be used as an
auxiliary adenocarcinoma marker in the differential diag-
nosis of poorly differentiated cervical carcinomas. Ac-
cording to our results, HNF-1β can be considered an
adenocarcinoma marker while p63/p40 and D2-40 are
highly specific markers of SCC with variable sensitivity.
Optimal results can be achieved by using these markers
in a panel. Limitation of the utility of HNF-1β includes
expression in benign glands, which preclude use of this
marker in the differential diagnosis of benign lesions and
well differentiated p16 negative types of cervical adeno-
carcinoma. Also, the positivity of HNF-1β in a subset of
endometrioid adenocarcinoma prevents the use of this
marker in the differential diagnosis between endome-
trioid and endocervical type of adenocarcinoma.
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